By using GEPIA (42), we found that TRIM6 expression was not correlated with the overall survival of CRC (Figure S2B), but it was negatively correlated with the disease-free survival of CRC (Figure S2C), suggesting that TRIM6 could constitute a useful prognostic marker to identify patients who are more likely to have disease recurrence and are, thus, good candidates to receive an aggressive adjuvant treatment. Here, TRIM6 is linked to colorectal carcinoma.